Incyte | INCY - Equity Capital And Reserves

Stock Price
107.10
Daily Change
4.34 4.22%
Monthly
-3.14%
Yearly
44.48%
Q1 Forecast
96.99

Incyte reported $4.65B in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Agios Pharmaceuticals USD 1.28B 85.22M Sep/2025
Alnylam Pharmaceuticals USD 233.89M 16.7M Sep/2025
Amgen USD 9.62B 2.19B Sep/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.06B 29.6M Sep/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Eli Lilly USD 23.79B 5.52B Sep/2025
Exelixis USD 2.16B 127.16M Sep/2025
Gilead Sciences USD 21.46B 1.78B Sep/2025
Incyte USD 4.65B 480.29M Sep/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
MacroGenics USD 67M 20.38M Sep/2025
Merck USD 51.85B 2.79B Sep/2025
Moderna USD 9.33B 69M Sep/2025
Neurocrine Biosciences USD 3B 309.3M Sep/2025
Novartis USD 44.75B 2.7B Sep/2025
Novartis USD 44.33B 2.28B Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
PTC Therapeutics USD -155.76M 50.79M Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Sarepta Therapeutics USD 1.32B 37.26M Sep/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Vertex Pharmaceuticals USD 17.32B 143.4M Sep/2025